Pregravid preparation of diabetic women
- 作者: Grigoryan OR1, Volevodz NN1, Andreeva EN1
-
隶属关系:
- 期: 卷 88, 编号 7 (2016)
- 页面: 114-119
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.07.2016
- URL: https://ter-arkhiv.ru/0040-3660/article/view/32037
- ID: 32037
如何引用文章
全文:
详细
Pregnancy in women with type 1 or 2 diabetes mellitus (DM) is associated with an increased risk for complications in both the mother and her fetus. The impact of these complications on modifiable risk factors may substantially improve pregnancy outcomes and reduce malformation rates in children. This is a goal of pregravid preparation (PGP) in this category of patients. The review gives the main points of PGP in patients with types 1 and DM and shows the results of main studies providing evidence for PGP in DM. In particular, by the moment of conception, DM patients should achieve a glycosylated hemoglobin (HbA1c) goal of <6% no later than 4 weeks before conception and during the first trimester of pregnancy, take folic acid in a high dose (at least 4000 µg, or 4 mg, daily), quit tobacco smoking and alcohol use, receive potentially teratogenic drugs, and, if need be, lose weight (the target body mass index of <27 kg/m2).
参考
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007
- Shawe J, Smith P, Stephenson J. Use of contraception by women with type 1 or type 2 diabetes mellitus: ‘it’s funny that nobody really spoke to me about it’. Eur J Contracept Reprod Health Care. 2011;16(5):350-358. doi: 10.3109/13625187.2011.597896
- Pedersen LM, Tygstrup I, Pedersen J. Congenital malformations in newborn infants of diabetic women. Correlation with maternal diabetic vascular complications. Lancet. 1964;1(7343):1124-1126. doi: 10.1097/00006254-196410000-00018
- Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMCPregnancy and Childbirth. 2006;6:30. doi: 10.1186/1471-2393-6-30
- Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30(7):1920-1925. doi: 10.2337/dc07-0278
- Fuhrmann K, Reiher H, Semmler K. Prevention of malformations in infants of insulin-dependent diabetic mothers. Diabetes Care. 1983;6(3):219-223. doi: 10.2337/diacare.6.3.219
- Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconceptional diabetic control: A comparative study. Am J Obstet Gynaecol. 1986;155(2):293-297. doi: 10.1016/0020-7292(87)90271-2
- Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, Aarons JH, Brown Z, Reed GF, Bieber FR. Lack of relation of increased malformation rates in infants of diabetic mothers to glycaemic control during organogenesis. N Engl J Med. 1988;318(11):671-676. doi: 10.1016/0020-7292(89)90576-6
- Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Pre-conception care of diabetes: glycaemic control prevents congenital anomalies. JAMA. 1991;265(6):731-736. doi: 10.1001/jama.265.6.731
- Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ. 1990;301(6760):1070-1074. doi: 10.1136/bmj.301.6760.1070
- Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol. 1991;77(6):846-849. doi: 10.1016/0020-7292(92)90749-9
- Willhoite MB, Bennert HW Jr, Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH. The impact of preconception counseling on pregnancy outcomes. The experience of the Maine Diabetes in Pregnancy Program. Diabetes Care. 1993;16(2):450-455. doi: 10.2337/diacare.16.2.450
- Cousins L. California diabetes and pregnancy Programme: a statewide collaborative program for the pre-conception and prenatal care of diabetic women. Baillieres Clin Obstet Gynaecol. 1991;5(2):443-459. doi: 10.1016/s0950-3552(05)80106-3
- Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care. 2006;29(8):1744-1749. doi: 10.2337/dc05-2265
- Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, Soo SC, Kelly S, Lim B, Randall J, Thompsett S, Temple RC. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514-2520. doi: 10.2337/dc10-1113
- NICE guideline 63: diabetes in pregnancy. Management of diabetes and its complications in pregnancy from the pre-conception to the postnatal period (last update 2015). Accessed May 24, 2016. Available at: https://www.nice.org.uk/guidance/ng3
- Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, Soo SC, Kelly S, Lim B, Randall J, Thompsett S, Temple RC. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514-2520. doi: 10.2337/dc10-1113
- Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832-1835. doi: 10.1097/00006254-199306000-00005
- Кузнецова И.В., Коновалов В.А. Применение фолиевой кислоты в процессе прегравидарной подготовки и во время беременности. Российский вестник акушера-гинеколога. 2015;15(1):24-31.
- Oyama K. Folic acid prevents congenital malformations in the offspring of diabetic mice. Endocr J. 2009;56(1):29-37. doi: 10.1507/endocrj.K08E-180
- Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with Type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22(12):1774-1777. doi: 10.1111/j.1464-5491.2005.01784.x
- Figo Working Group On Best Practice In Maternal-Fetal Medicine. Best practice in maternal-fetal medicine. Int J Gynaecol Obstet. 2015;128(1):80-82. doi: 10.1016/j.ijgo.2014.10.011
- Гродницкая Е.Э. Фолацин в профилактике дефектов нервной трубки. Журнал акушерства и женских болезней. 2010;LIX(3):87-91.
- Richard KM, Peters P. Vitamins, minerals and trace elements. Folic acid. In: Schaefer C, Peters P, Miller RK, eds. Drugs During Pregnancy And Lactation: Treatment Options And Risk Assessment. (Third Edition). Academic Press; 2015.
- Плужникова Т.А. Опыт применения фолацина у женщин с репродуктивными потерями и гипергомоцистеинемией. Проблемы репродукции. 2008;2:77-79.
- Инструкция по медицинскому применению лекарственного препарата Фолацин, АО «Ядран» Галенский Лабораторий (Хорватия), регистрационное удостоверение №ЛС-001513 от 10.08.2010. Ссылка активна на 24.05.2016. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=86760&t=
- Temple R. Preconception care for women with diabetes: is it effective and who should provide it? Best Pract Res Clin Obstet Gynaecol. 2011;25(1):3-14. doi: 10.1016/j.bpobgyn.2010.10.001
补充文件
![](/img/style/loading.gif)